Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice

[1]  X. Navarro,et al.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement. , 2013, Stem cells and development.

[2]  Andreas Marg,et al.  Dysferlin-Peptides Reallocate Mutated Dysferlin Thereby Restoring Function , 2012, PloS one.

[3]  J. Fonseca,et al.  Effective treatment of rat adjuvant-induced arthritis by celastrol. , 2012, Autoimmunity reviews.

[4]  K. Moudgil,et al.  Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines. , 2012, Bioorganic & medicinal chemistry.

[5]  T. Partridge,et al.  Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response , 2012, Neuromuscular Disorders.

[6]  J. Stains,et al.  Celastrus and Its Bioactive Celastrol Protect against Bone Damage in Autoimmune Arthritis by Modulating Osteoimmune Cross-talk* , 2012, The Journal of Biological Chemistry.

[7]  K. Campbell,et al.  Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice , 2011, Skeletal Muscle.

[8]  E. Hoffman,et al.  Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice , 2011, BMC cardiovascular disorders.

[9]  N. Lévy,et al.  Translational Research and Therapeutic Perspectives in Dysferlinopathies , 2011, Molecular medicine.

[10]  J. Yamate,et al.  Comparative Gene Expression Analysis in the Skeletal Muscles of Dysferlin-deficient SJL/J and A/J Mice , 2011, Journal of toxicologic pathology.

[11]  Eric P Hoffman,et al.  Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice , 2011, Journal of cardiovascular pharmacology and therapeutics.

[12]  J. Lueck,et al.  Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. , 2010, The Journal of clinical investigation.

[13]  E. Hoffman,et al.  Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype , 2010, PloS one.

[14]  V. Mouly,et al.  Therapeutic exon ‘switching’ for dysferlinopathies? , 2010, European Journal of Human Genetics.

[15]  N. Bourg,et al.  Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. , 2010, Human molecular genetics.

[16]  V. Laporte,et al.  Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease , 2010, Journal of Neuroinflammation.

[17]  J. T. Dunnen,et al.  Therapeutic exon skipping for dysferlinopathies? , 2010, European Journal of Human Genetics.

[18]  L. Shultz,et al.  Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B. , 2009, The American journal of pathology.

[19]  E. Hoffman,et al.  A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. , 2009, International immunopharmacology.

[20]  G. S. Pandey,et al.  Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures , 2009, Muscle & nerve.

[21]  E. Hoffman,et al.  Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. , 2008, The American journal of pathology.

[22]  E. Hoffman,et al.  Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart , 2008, Neuromuscular Disorders.

[23]  E. Hoffman,et al.  Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. , 2008, The American journal of pathology.

[24]  B. Aggarwal,et al.  Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. , 2007, Blood.

[25]  M. Beal,et al.  Celastrol Blocks Neuronal Cell Death and Extends Life in Transgenic Mouse Model of Amyotrophic Lateral Sclerosis , 2006, Neurodegenerative Diseases.

[26]  Simon C Watkins,et al.  Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. , 2004, Human molecular genetics.

[27]  R. Rojas-García,et al.  Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients , 2001, Neurology.

[28]  K. Bushby,et al.  Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation , 2001, Neuroreport.

[29]  K. Bushby,et al.  Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B , 1999, Nature Genetics.

[30]  Pieter J. de Jong,et al.  Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy , 1998, Nature Genetics.

[31]  J. Beckmann,et al.  A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B , 1998, Nature Genetics.

[32]  J. Faulkner,et al.  Contractile properties of skeletal muscles from young, adult and aged mice. , 1988, The Journal of physiology.